ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission
August 7, 2015 8:36 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $49.00 (from $38.00) following Q2 results and ahead of NDA submission.
Carr commented, "Acadia hosted a quarterly conference call last night. Mgmt guided for Nuplazid NDA... More
Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
August 7, 2015 7:02 AM EDTPiper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $48.00 (from $39.00), saying with the Pima' NDA filed the next steps may be more challenging.
Analyst Charles Duncan commented, "ACADIA ended 2Q with $271M in cash,... More
Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15
August 7, 2015 6:56 AM EDTCowen reiterated an Outperform rating on Acadia Pharmaceuticals (NASDAQ: ACAD), and raised the price target to $50.00 (from $43.00), following 2Q15 results. ACAD reported 2Q15 EPS of $(0.39) vs consensus of $(0.33).
Analyst Ritu Baral commented, "ACAD's 2Q15 call was largely uneventful with ACAD... More
Acadia Pharma (ACAD) Misses Q2 EPS by 6c
August 6, 2015 4:15 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More